High patient satisfaction and improved cosmetic outcomes after a 3-day field treatment of actinic keratoses with ingenol disoxate on the face, chest, and balding scalp

Introduction and Objectives: Ingenol disoxate (IngDsx, LEO 43204) is a novel ingenol derivative selected based on improved thermostability and biologic properties over those of ingenol mebutate (IngMeb). Previous studies demonstrated satisfaction and cosmetic improvements in patients treated with IngMeb. As part of a phase 2 trial, we investigated these outcomes for field treatment with IngDsx in patients with actinic keratoses (AK) on face/chest (F/C) and scalp (S) (NCT02305888).

http://ift.tt/2sewg5X